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ABSTRACT
Changes in virological and immunological parameters were analysed following structured intermittent
interruption of highly active anti-retroviral therapy (HAART) of patients with chronic human
immunodeﬁciency virus (HIV) infection. Parameters analysed were serum levels of the CD8+ T-cell-
derived inhibitory molecules interleukin-16 (IL-16), monocyte inhibitory protein-1b (MIP-1b) and
RANTES (‘regulated upon activation, normal T-cell expressed and presumably secreted’), and the
enhancer of HIV replication, monocyte chemotactic protein-1 (MCP-1). Twenty-ﬁve patients with
chronic HIV infection were evaluated during three cycles of intermittent interruptions of therapy
(8 weeks on ⁄ 4 weeks off) in comparison with 20 healthy sex- and age-matched controls. At enrolment,
HIV-infected patients showed signiﬁcantly higher serum concentrations of IL-16 and RANTES, and
signiﬁcantly lower concentrations of MCP-1, than did healthy controls. Levels of MIP-1b were similar in
both groups. Only the serum levels of IL-16 increased signiﬁcantly in HIV-infected patients after every
treatment interruption. However, differences between the CD4+ or CD8+ T-cell counts ⁄lL, HIV loads
and serum concentrations of each cytokine at baseline and at the end of the three cycles of intermittent
interruptions of therapy were not signiﬁcant. It was concluded that structured intermittent interruption
of HAART for patients with chronic HIV infection did not modify the immunological parameters,
including serum levels of CD8+ T-cell-derived inhibitory molecules, or the virus parameters studied.
Thus, the ﬁndings do not support the use of this treatment modality for the management of
HIV-infected patients.
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INTRODUCTION
It has been demonstrated clearly that latently
infected, resting CD4+ T-cells carrying replica-
tion-competent human immunodeﬁciency virus
(HIV) are present in infected patients [1]. Such cells
constitute a major impediment to the withdrawal
of therapy, because they persist in patients in
whom virus levels in plasma have been driven
below the level of detection by highly active
anti-retroviral therapy (HAART) [2]. Following
discontinuation of therapy, all patients experience
rapid rebounds in virus counts and loss of CD4+
T-lymphocytes [3]. In this respect, immune-medi-
ated containment of virus replication in this reser-
voir is particularly relevant in the light of attempts
to interrupt the administration of HAART in HIV-
infected patientswhose viraemia iswell-controlled
following treatment. One strategy involves struc-
tured treatment interruption (STI),with alternating
on and off cycles of HAART [4]. The theory
supporting the use of STI in individuals who had
been treated successfully with HAART was that
allowing short bursts of plasma viraemia would
provoke HIV-speciﬁc immune responses [5]. Data
from human [4] and animal models [6] support the
use of ‘autovaccination’ in acute HIV-1 infection
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(i.e., before seroconversion). However, it has not
been proved that STI provides a signiﬁcant beneﬁt
in patients with chronic HIV infection with regard
to controlling the HIV load or preserving levels of
CD4+ T-cell counts [7,8].
A few retrospective reports have suggested that
some HIV-speciﬁc CD8 T-cell responses could be
re-ampliﬁed in HIV-infected patients whose ther-
apy was interrupted in an unstructured manner
[9,10]. Moreover, controlled studies demonstrated
that exposure to HIV-1 antigen produced a
substantial and maintained increase in HIV-spe-
ciﬁc CD8 T-cell responses in at least 30% of
patients [11-13]. However, no correlation could be
found between the magnitude of CD8+ T-cell
responses and the virus load observed after
cessation of therapy [4,7]. This indicated that
immune control of HIV is more complex than that
characterised by CD8+ T-cell responses alone to a
panel of cytotoxic T-lymphocyte epitopes. Other
components of the immune system, including
humoral immunity [14], antigen-presenting cells,
natural killer cells and soluble factors [13], must
be included to gain a better understanding of the
determinants of the virus load observed after
cessation of therapy, and to identify more prom-
ising strategies to enhance the immune control of
HIV replication. Soluble factors include interleu-
kin (IL)-16, produced by activated CD8+ T-cells
[15], noteworthy for functioning as a speciﬁc
ligand for CD4, which is adopted by HIV as the
primary receptor enabling attachment to target
cells [15], and b-chemokines, such as monocyte
inhibitory protein-1b (MIP-1b) and RANTES
(‘regulated upon activation, normal T-cell
expressed and presumably secreted’), which
block entry of HIV by competing for binding to
the co-receptor [16–19].
When the role of soluble CD8+ T-cell factors
was examined in relation to suppression of HIV in
the latent CD4+ T-cell reservoir, b-chemokines
played a major role in the containment of virus
replication for some long-term non-progressors,
and for all infected patients who were receiving
HAART and in whom treatment was initiated
during the chronic phase of HIV infection [13].
Likewise, a signiﬁcant increase in serum IL-16
level has been shown in HIV-infected patients
following HAART, coinciding with an exponen-
tial decline of HIV RNA levels in plasma [20]. In
contrast, the b-chemokine monocyte chemo-
tactic protein-1 (MCP-1) functions by actively
enhancing HIV replication in mononuclear cell
cultures derived from HIV-infected individuals
[21]. Together, these features suggest the existence
of a dynamic balance between a range of cytok-
ines and HIV disease progression.
Therefore, in an attempt to clarify the nature of
the in-vivo interactions between HIV replication
and production of chemokines, the present study
assessed changes in plasma virus load, peripheral
blood T-cell sub-populations, and circulating
levels of IL-16 and the chemokines MIP-1b,
RANTES, and MCP-1, in a group of patients with
HIV infection following STI.
PATIENTS AND METHODS
Patients
Twenty-ﬁve patients with chronic HIV infection were ana-
lysed. Inclusion criteria were: (1) a minimum CD4+ T-cell
count, before receiving HAART, of > 350 ⁄lL; (2) a CD4+ T-cell
count of > 500 ⁄ lL at enrolment in the study; (3) an HIV RNA
level of < 50 copies ⁄mL during the previous 6 months; and (4)
HAART, consisting of at least a three-drug regimen, for at least
12 months. Exclusion criteria were: (1) a history of opportu-
nistic infections [22]; (2) a clinical history compatible with lack
of compliance; (3) a history of changed treatment because of
virological failure. The characteristics of the patients included
in the study are presented in Table 1. For the analysis of serum
cytokine concentrations, 20 age- and sex-matched healthy
individuals (median age, 34 years; interquartile range,
30–38 years; male ⁄ female ratio, 8:2) were selected as controls.
Study schedule
The schedule of STI comprised 8 weeks with HAART and
4 weeks without HAART. At the end of each phase (on and
off), medical assessments were conducted, including clinical
history and physical examination, CD4+ and CD8+ T-cell
counts, determination of HIV load, and determination of
cytokine levels. Because of concern regarding the possible
Table 1. Characteristics of the patients studied
Parameter Value
Age (years) 39 (37–45)
Male ⁄ female ratio 17:8
Parenteral drug use as a risk factor for HIV infection, n (%) 12 (48)
Time from diagnosis of HIV infection until the start
of the study (months)
84 (57–147)
Minimum CD4+ T-cell count ⁄ lL 425 (372–588)
CD4+ T-cell count ⁄ lL at the beginning of the study 769 (539–1196)
Maximum HIV virus load (mean ± SD), copies ⁄mL · 1000 35 (12–354)
Number of HAART regimens previous to study regimen 1 (0–2)
Time under HAART regimen (months) 60 (49–75)
Study HAART regimen, n (%)
Zidovudine + lamivudine + indinavir 4 (16)
Zidovudine + didanosine + nelﬁnavir 3 (12)
Zidovudine + didanosine + ritonavir + saquinavir 4 (16)
Zidovudine + lamivudine + lopinavir 6 (24)
Stavudine + lamivudine + indinavir 6 (24)
Stavudine + lamivudine + nelﬁnavir 2 (8)
Except where indicated, data are presented as medians (interquartile ranges).
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development of potential resistance to and ⁄or loss of efﬁcacy
of HAART, an analysis of the treatment response was
performed after each cycle. HAART was discontinued for
another period only in patients whose plasma virus load
decreased to < 50 copies ⁄mL after therapy re-initiation. It was
also decided that the trial would be stopped if, among the 25
patients, two or more failed to suppress viraemia to < 50
copies ⁄mL following re-initiation of therapy. The study
protocol was approved by the Institutional Ethics Committee,
and all patients gave their informed consent.
Laboratory determinations
CD4+ andCD8+T-cell countsweredetermined by standardﬂow
cytoﬂuorimetry. Serum HIV load was determined by reverse
transcription PCR (Amplicor HIV; Roche Diagnostics, Basel,
Switzerland), with a sensitivity of 50 RNA copies ⁄mL of serum.
Blood samples, collected in sterile Vacutainer tubes (Becton-
Dickinson, Meylan, France), were centrifuged (3500 g for
15 min at 4C) and serum was stored at ) 80C in pyrogen-
free polyethylene tubes (Biofreeze; Costar, Cambridge, MA,
USA) until cytokines were assayed. Serum levels of IL-16, MIP-
1b, RANTES and MCP-1 were determined with ELISA kits (R
& D Systems, Minneapolis, MN, USA), used according to the
manufacturer’s instructions, with detection limits (lowest
positive standard) of: IL-16, 1 pg ⁄mL; MIP-1b, 11 pg ⁄mL;
RANTES, 5 pg ⁄mL; and MCP-1, 5 pg ⁄mL.
Statistical analysis
Data are presented as median and interquartile ranges or,
where indicated, as absolute numbers and percentages. The
data from two independent groups were compared with use of
the Mann–Whitney U-test. The signiﬁcance of parameters
within each group was tested with the Wilcoxon matched-
pairs signed-rank test. For qualitative variables, chi-square
with Yates’ correction or Fisher’s exact test was used. A
p value of < 0.05 was considered signiﬁcant. The statistical
analyses were performed with SSPS v. 11.0 software (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Evolution of immunological and virological
parameters of the patients
No HIV-related opportunistic diseases were
observed during STI. Likewise, the acute retroviral
syndrome was not detected in any patient. Table 2
shows the evolution of CD4+ and CD8+ T-cell
counts and plasma HIV loads in the 25 patients
enrolled to receive STI. A signiﬁcant decrease in
CD4+ T-cell counts was evident after each treat-
ment interruption, with recuperation after
re-introduction of HAART. Differences between
CD4+ and CD8+ T-cell counts at the beginning and
the end of the study were not signiﬁcant. The HIV
load decreased to < 50 copies ⁄mL after the
re-initiation of therapy in every one of the STI
cycles.
Cytokines
HIV-infected patients had signiﬁcantly higher
serum concentrations of IL-16 and RANTES, and
signiﬁcantly lower concentrations of MCP-1, than
did healthy controls; serum levels of MIP-1b were
similar in both groups, with the following median
(interquartile range) values (pg ⁄mL): IL-16, 141.5
(87.4–204.3) vs. 81.2 (46.4–86.9), p < 0.01; MIP-1b,
44.3 (0–68.7) vs. 80.3 (16.9–143.1), p > 0.05;
RANTES, 394.3 (162.8–439.3) vs. 50.2 (26.1–73.9),
p < 0.001; and MCP-1, 19.2 (6.9–27.4) vs. 36.5
(12.1–65.9), p 0.034. No signiﬁcant correlation was
detected between the serum concentrations of
these cytokines and either CD4+ or CD8+ T-cell
counts.
Fig. 1 shows the concentrations of each of the
cytokines during the follow-up of these patients.
Serum levels of IL-16 increased signiﬁcantly
after every treatment interruption. Likewise,
concentrations of MCP-1 increased after every
interruption, although a statistically signiﬁcant
increase was observed following the ﬁrst cycle
only. In contrast, a non-signiﬁcant decrease in
RANTES level was detected between the phases
with and without HAART in each of the cycles.
However, differences between the serum con-
Table 2. Effects of long-cycle structured intermittent therapy on median CD4+ and CD8+ T-cell counts and plasma HIV
load in 25 patients receiving structured treatment interruption
First cycle Second cycle Third cycle
End of study
HAART onHAART on HAART off HAART on HAART off HAART on HAART off
CD4+ T-cell
count ⁄ lL
769 (539–1196) 721 (535–984) 910 (786–1308) 754 (448–911) 845 (620–1228) 637 (469–895) 810 (544–1050)
CD8+ T-cell
count ⁄ lL
1415 (971–2545) 1346 (1307–1733) 1421 (1339–1704) 1379 (1134–1905) 1416 (1203–1795) 1270 (897–2115) 1443 (1045–1863)
HIV viral load,
copies ⁄mL · 1000
< 50 47 (3–243) < 50 53 (5–266) < 50 59 (4–79) < 50
Data are presented as medians (interquartile ranges).
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centrations of each cytokine at baseline and at
the end of the study were not signiﬁcant
(p > 0.05 in each case).
DISCUSSION
The present study analysed the effect of long-
cycle STI on the concentrations of CD8+ T-cell-
derived soluble factors implicated in the immune
response to HIV. Immune responses generated in
HIV-infected individuals play an important role
in controlling viraemia. In this respect, the emer-
gence of HIV-speciﬁc CD8+ T-cytotoxic lympho-
cyte activity coincides with the clearance of
viraemia during primary HIV infection, while a
decline in the CD8+ T-cytotoxic response is
associated with disease progression in infected
individuals [23]. At least two types of CD8+ T-
cell-mediated antivirus activity have been des-
cribed in HIV infection. The ﬁrst is a suppressive
activity against HIV, involving lysis of infected
cells in an antigen-speciﬁc fashion restricted by
the major histocompatibility complex [24], while
the second mechanism inhibits virus replication
via soluble factors in the absence of cell killing
[25,26]. The CD8+ T-cytotoxic response has been
analysed previously in HIV-infected patients after
STI and, although a substantial and maintained
increase in HIV-speciﬁc CD8 T-cell responses was
observed in at least 30% of patients [11–13], the
immune responses were transitory and unable to
modify signiﬁcantly the pre-HAART equilibrium
between cellular immunity and virus replication
[27]. However, inhibition of virus replication via
soluble factors has not been analysed previously
in this situation.
There is increasing awareness of the funda-
mental contribution made by cytokines in deter-
mining the outcome of HIV infection. IL-16 and
the b-chemokines MIP-1b and RANTES function
in an additive manner to inhibit infection of
CD4+ T-cells by HIV strains [15–21,28]. IL-16 is a
speciﬁc ligand for CD4, which is the well-
documented receptor for major histocompatibil-
ity complex class II molecules and the primary
receptor necessary for entry of HIV into target
cells [15]. The chemokine receptor CCR-5, spe-
ciﬁc for these b-chemokines, is the second
receptor for HIV entry into these cells [16–19].
In contrast, MCP-1 augments HIV replication in
mononuclear cell cultures [21]. Increased serum
concentrations of IL-16, MIP-1b and RANTES,
and a decreased concentration of MCP-1, in
patients with chronic HIV infection treated with
HAART for whom the HIV load in serum is
undetectable, have been demonstrated previ-
ously [13,20]. The present study also showed
increased serum levels of IL-16 and RANTES
and decreased MCP-1 levels in HIV patients
with chronic infection treated with anti-retroviral
agents.
A favourable effect of STI on these immune
molecules was only demonstrated temporarily for
serum levels of IL-16, in that an increase in IL-16
concentration was detected after every period
without HAART. However, at the end of the
Fig. 1. Serum concentrations of
interleukin (IL)-16, monocyte inhib-
itory protein-1b (MIP-1b), RANTES
(‘regulated upon activation, normal
T-cell expressed and presumably
secreted’) and monocyte chemotac-
tic protein-1 (MCP-1) in patients
with chronic human immuno-
deﬁciency virus infection, after three
cycles of structured intermittent
interruption of highly active
anti-retroviral treatment (8 weeks
on ⁄ 4 weeks off).
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study period (three cycles), no difference in IL-16
levels was observed compared with values at
baseline. Likewise, similar values of MIP-1b,
RANTES and MCP-1 were observed at enrolment
and at the end of the study.
Treatment interruption proved to be quite safe
in this population. Possible risks for patients in
whom STI has been implemented include symp-
tomatic acute retroviral syndrome, re-seeding of
virus reservoirs, a decline in CD4+ T-cell count, a
greater risk of HIV transmission, selection of
HIV drug resistance, and poor adherence to
subsequent continuous therapy [8]. However, for
the patients included in the present study, no
clinical data suggesting acute retroviral syn-
drome or opportunistic events were recorded.
Moreover, in contrast to the ﬁndings in some
other studies on the same subject [8,29-31], none
of the patients subjected to long-cycle STI
(8 weeks on ⁄ 4 weeks off) failed to suppress
viraemia to < 50 copies ⁄mL following re-initia-
tion of therapy. There have been similar ﬁndings
in other studies [32,33]. These contrasting results
could be associated with differences among
patients with regard to previous HAART ther-
apy and, consequently, with resistance to the
treatment. It should be noted that the present
study did not enrol any individuals who had
been exposed to partially effective treatment
before HAART, thus eliminating a group at high
risk for the development of resistance. The
present data, as well as those reported previ-
ously [6–12,30–32], did not demonstrate signiﬁ-
cant modiﬁcations in CD4+ or CD8+ T-cell counts
or better control of HIV load following succes-
sive interruptions of therapy. These ﬁndings,
together with an absence of favourable changes
in the concentrations of serum cytokines, do not
support the use of STI or autovaccination in the
management of chronic HIV infection.
The present study was begun before the
appearance of the current guidelines for HIV
treatment [34]. Nowadays, HAART is initiated in
patients without previous opportunistic disease if
the CD4+ T-cell count is < 350 ⁄mL. Thus, changes
in guidelines could discount the use of STI in
patients with an acceptable level of immunocom-
petence. Moreover, if a beneﬁt in terms of
immunological or virological parameters is not
evident, as was demonstrated in the present
study, the use of this treatment should be
questioned.
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